Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ensysce Biosciences Inc ENSC

Alternate Symbol(s):  ENSCW

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology... see more

Recent & Breaking News (NDAQ:ENSC)

Ensysce Biosciences Announces Completion of $8 Million Convertible Note Financing

ACCESS Newswire August 9, 2022

Ensysce Biosciences Announces Positive Bioequivalence (BE) Study Data of Novel "TAAP" Opioid PF614 and Provides Timing of Corporate Update Call

ACCESS Newswire July 27, 2022

Ensysce Biosciences Announces Initial Patients Dosed of First Human Abuse Potential Study

ACCESS Newswire July 13, 2022

Ensysce Biosciences Secures $8 Million Convertible Note Financing

ACCESS Newswire July 1, 2022

Ensysce Biosciences Receives Notice of Award for 4th Year of Funding for Its Multi-Pill Abuse Resistance (MPAR(TM)) Platform

ACCESS Newswire June 27, 2022

Ensysce Biosciences Reminds Shareholders to Vote At Upcoming 2022 Virtual Annual Shareholder Meeting

ACCESS Newswire June 21, 2022

Ensysce Biosciences Announces Initiation of First Human Abuse Potential Study

ACCESS Newswire May 23, 2022

Ensysce Biosciences Provides Business Update and Reports First Quarter 2022 Financial Results

ACCESS Newswire May 12, 2022

Ensysce Biosciences Releases 2021 Annual Shareholder Letter

ACCESS Newswire May 5, 2022

Ensysce Biosciences Announces New Clinical Results from Trials PF614-102 and PF614-MPAR-101

ACCESS Newswire May 5, 2022

Dr. Lynn Kirkpatrick, Invited Speaker at SMi 22nd Annual Pain Therapeutics Conference in London UK

ACCESS Newswire April 20, 2022

Ensysce Biosciences Announces Appointment of Dr. Nily Osman as Chief Medical Officer

ACCESS Newswire April 18, 2022

Ensysce Biosciences Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

GlobeNewswire March 31, 2022

Ensysce Biosciences Announces Fourth Quarter and Full Year 2021 Earnings Release Date and Timing of Corporate Update Call

ACCESS Newswire March 24, 2022

Ensysce Biosciences Announces Participation in the 34th Annual Roth Conference

GlobeNewswire February 23, 2022

Ensysce Biosciences Appoints Industry Veteran Lee Rauch to Board of Directors

GlobeNewswire February 8, 2022

Ensysce Biosciences Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communication Program

GlobeNewswire January 31, 2022

Ensysce Biosciences Announces Results of Special Meeting of Stockholders

GlobeNewswire January 27, 2022

Ensysce Biosciences Reminds Stockholders to Vote at Upcoming Special Meeting

GlobeNewswire January 19, 2022

Ensysce Biosciences Announces First Cohort Dosing in Bioequivalence (BE) Study of Novel "TAAP" Opioid

GlobeNewswire January 10, 2022